Charles River Laboratories International Inc. (CRL) exhibits 41.0% gross margins and 0.4% return on invested capital within Health Care (Biotechnology: Commercial Physical & Biological Resarch), balanced against a 95.0x enterprise multiple and 7.4% implied options volatility.
Sustained 41.0% gross profitability converts into 0.6% operating margin and 0.4% ROIC, outpacing sector cost of capital.
ROIC: 0.4% // GM: 41.0%YoY revenue trajectory of -0.9% paired with 3.10% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -0.9% // FCF YLD: 3.10%Altman Z-Score of 3.65 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.65 // F-SCORE: 6/9Trading at 24.0x trailing P/E (23.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 95.0xOptions market prices a ±7.4% implied move with a 0.72 put/call ratio around $369.00 max pain.
IMPL MOVE: ±7.4% // P/C: 0.72Elevated industry capital intensity and customer concentration in Biotechnology: Commercial Physical & Biological Resarch require continuous execution to defend -3.6% net margins.
NET MARGIN: -3.6% // D/E: 0.52x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for CRL & activate live FRED threshold breach alerts.